News Hub | News Direct

Lifestyle

Beverage: Coffee/Tea/Non-Alcoholic Beverage: Spirits/Beer/Wine Casino/Gaming Fashion Food/Cooking/Baking Health & Fitness Home Goods Hospitality Leisure Activities & Hobbies Parenting Pets Photography Seniors Travel & Tourism
Article thumbnail News Release

Can Someone Explain the Snail Secretion Skincare Craze?

Caracol Natural Skincare

Caracol Natural Skincare, NEW to the US, is a natural skincare brand that uses snail secretion as the key ingredient. Steeped in tradition, this Chilean based family-owned skincare brand has combined Chilean ancient medicine with modern technology and is now available in the US on AMAZON. Founded in 2006, Caracol Natural is a beautiful story of people in harmony with nature, with high admiration for Chilean and global ancestral medicine, and with the conviction that skincare with natural eco-friendly ingredients, along with premium actives, can offer better-faster-stronger results. The use of snail secretion (also known as snail mucin) in cosmetics can be traced back to ancient Greece, where Hippocrates reportedly prescribed snails for skin inflammation. In the 20th century, snail farmers in Chile noticed that their hands became softer and smoother after handling snails, which led to the development of snail-based creams for hand care. The use of snail secretion in skincare products again gained popularity in the 1990s, when a group of Chilean farmers developed a snail cream that became a best-seller in Korea. Since then, snail secretion has been incorporated into a wide range of skincare products, including creams, serums, masks, and lotions. One of the most interesting aspects of snail secretion is its ability to improve skin health in multiple ways. Snail secretion is a complex mixture of compounds, including hyaluronic acid, glycolic acid, allantoin, antioxidants, and peptides, that can work together to provide a range of benefits for the skin. Another interesting aspect of snail secretion is that it is a natural ingredient that is sustainably sourced. Snail farming is a relatively low-impact agricultural practice that doesn't require large amounts of water or land, making it an environmentally friendly option. Here are some of the main benefits of snail secretion: Hydration: Snail secretion contains hyaluronic acid, glycolic acid, and allantoin, which help to hydrate and moisturize the skin. This can help to reduce the appearance of fine lines and wrinkles, and leave the skin looking plump and supple. Anti-aging: Snail secretion contains antioxidants, peptides, and other compounds that can help to reduce the signs of aging. It may help to improve skin elasticity, reduce the appearance of dark spots, and improve skin texture. Healing: Allantoin, a compound found in snail secretion, has been shown to have wound-healing properties. It may help to reduce inflammation, speed up the healing process, and reduce the risk of scarring. Soothing: Snail secretion has a soothing effect on the skin, which can help to reduce redness and irritation. This makes it particularly beneficial for people with sensitive skin. Brightening: Snail secretion contains glycolic acid, which can help to brighten the skin and reduce the appearance of dark spots and hyperpigmentation. The Caracol Natural lineup includes: The Gentle Cleanser - $22.99 The Gentle Cleanser Facial Foam Expert gently removes impurities while respecting your natural skin barrier. This gentle face wash formula includes Snail Secretion Filtrate plus 8 Clearing Vegetal Extracts like Nettle, Aloe Vera, Sage and Rosemary that helps restore skin balance. Our formula is fitter for sensitive, delicate, dry, flaky, worn, dull, sallow skin, nevertheless is recommended for balancing oily skin and suitable for all skin types The Eye Contour Serum - $32.99 The Eye Contour Serum hydrates, moisturizes, refreshes and restores the healthy appearance of the delicate skin around the eye. It helps to depuff, reduce dark circles and sagginess, lessen oxidative stress, minimize and prevent fine lines and crow's feet. Our Eye Contour Serum helps to brighten, firm, plump, lift, soothe and smooth skin to sustain and recover a radiant, lively and healthier look. The Gentle Serum - $35.99 The Premium Gentle Serum is designed to restore and maintain firmer, denser, flexible, healthier, radiant and bouncier skin. Our Skin Care Gentle Serum for Face and Neck helps subside fine lines, wrinkles, sagginess and dullness. It lessens oxidative stress, it hydrates, moisturizes, softens, calms, plumps, and boosts skin wellbeing, bestowing a beautiful and youthful complexion. Texture Reform Cream - $32.99 The Texture Reform Cream feels soft, silky, light, cool and fresh; it moisturizes and hydrates efficiently without leaving a greasy feeling; it appeals to anyone grease-averse. It helps to brighten up dull and lackluster skin, care for the balance of normal to oily skin, sensitized and acne prone skin (it is not medicinal), lessen oxidative stress, minimize and prevent the appearance of fine lines and wrinkles, keep in check aging and strengthen the skin barrier. Caracol Natural Skincare is NOW available on AMAZON. Contact Details CARACOL NATURAL SKINCARE Dianne Vavra / Spotlight Beauty +1 917-331-4869 Company Website https://caracol-skincare.com/en/

May 04, 2023 09:03 AM Eastern Daylight Time

Image
Article thumbnail News Release

Emergent Health to spin out subsidiary PharmaZu to its Shareholders pursuant to an IPO underwritten by a Nationally Recognized Investment Banking Firm

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it has executed a Term Sheet for a firm committed underwriting with a nationally recognized investment banking firm for $10,000,000 with respect to planned corporate financing transactions, including the private placement of securities (“pre-IPO Financings”) and the planned $10 million initial public offering of Emergent subsidiary PharmaZu common stock (“IPO”) that will be applied for listing on NASDAQ or NYSE/AMEX, with NO DILUTION to Emergent shareholders. PharmaZu is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including pet pharmacy, vet telehealth and pet wellness businesses. Upon the effectiveness of the IPO and listing on a national exchange, PharmaZu plans to acquire a 48-state authorized compounding pharmacy located in West Palm Beach, FL, doing approximately $10M a year in revenue, which will serve as the backbone and fulfilment center for PharmaZu, creating a national platform throughout the United States. Subsequently, Emergent plans to distribute to its shareholders, pro rata, the shares of PharmaZu as a dividend, when a record date is set. The raise of capital will be used for expanding PharmaZu’s business, product offerings, as well as for acquisitions. Jim Morrison, former L'Oréal President and Emergents full time CEO stated, “The transaction with Boustead will start a new exciting chapter for PharmaZu, while maximizing the value to Emergent’s shareholders.” Adam Books, President of PharmaZu stated, “PharmaZu is poised to start its disrupting of the mail order pet business and pet medications, as well as advancing the tele-pet med environment. I am very thrilled to be a part of this.” The execution of the Engagement Letter does not constitute a commitment by Boustead or the Company to consummate any transaction contemplated hereunder and does not ensure the successful placement of securities of any investment vehicle or the success of Boustead with respect to finding any investors or the success with respect to any transaction. No promises, representations or guarantees have been made. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website info@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 04, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Two Hands Corporation Announces Asset Sale of gocart.city

Two Hands Corporation

Two Hands Corporation, (CSE: TWOH) (OTC: TWOH) a Delaware company in the grocery and e-commerce sector, is pleased to announce the sale of its gocart.city business, including its e-commerce site, branding, Grocery Originals store, and inventory to a private buyer effective May 1, 2023. Under the terms of the Memorandum of Understanding (MOU), the buyer has acquired the assets of gocart.city. The sale includes the e-commerce site, branding, supporting components of the Grocery Originals store, and inventory. The ongoing sales and client base will also be transferred as part of the transaction. Two Hands CEO, Nadav Elituv, commented, "We believe this transaction is in the best interest of our shareholders and will allow us to focus on our core operations while reducing our debt by $134,700. We are confident in the buyer's ability to continue the growth and success of gocart.city." As part of our strategic plan to refocus on core operations, Two Hands will be dedicating resources towards its growing food service business. The company has seen growth and opportunities in this sector, with an increase in both the number of customers and sales. Two Hands has also strengthened relationships with strategic suppliers, resulting in better overall margins for the company. "We are excited about the growth and opportunities in our food service business and are committed to investing in its continued success," added Elituv ABOUT TWO HANDS CORPORATION Two Hands Corporation, (OTC: TWOH) is a food distribution company operating under the Cuore Food Services brand. Please visit our website at www.twohandsgroup.com This press release contains forward-looking statements that involve a number of risks and uncertainties. Any statement not regarding a historical fact is a forward-looking statement. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to, the company's ability to finance its planned expansion efforts; the company's ability to raise funds on acceptable terms; the company's ability to successfully adapt its business model and such other risks disclosed from time to time in the company's reports filed with the securities and exchange commission including those on the company's annual report on form 10-K. The company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in management's expectations, except as required by law. CONTACT: Two Hands Corporation IR@twohandsapp.com www.twohandsgroup.com www.gocart.city Contact Details Two Hands Corporation IR@twohandsapp.com

May 04, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Bragg Gaming reveals plans for expansion into new gaming markets in Europe and Mexico

Bragg Gaming Group

Bragg Gaming chief strategy officer Yaniv Spielberg joins Proactive's Natalie Stoberman to share the company's plans for expansion into Europe and Central America. Bragg Gaming Group is a fast-growing, vertically integrated, global business-to-business online gaming and content technology supplier. Its products and services collectively represent a full turnkey solution with everything required to set up and operate online and omni-channel casino, sportsbook and lottery brands. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 03, 2023 11:32 AM Eastern Daylight Time

Video
Article thumbnail News Release

Austin-based chief medical officer commits to health equity in Central Texas by joining local American Heart Association Board of Directors

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a leader in brain injury rehabilitation services, and The American Heart Association (AHA), the world’s leading nonprofit organization focused on heart and brain health for all, today announced Dr. Matthew Ashley as a new member of the AHA’s Board of Directors in Central Texas. Dr. Ashley is the chief medical officer for CNS. “I am honored to join the Central Texas American Heart Association board and serve our community by improving heart health and stroke awareness with the AHA,” said Dr. Ashley. “For nearly 100 years, the American Heart Association has been ensuring longer, healthier lives through innovative educational efforts including stroke prevention and treatment. I look forward to our partnership for large-scale community efforts focused on public education and awareness regarding brain injuries.” Earlier this year, the AHA and CNS announced that they are working together to deepen connections with healthcare providers, patients and caregivers while raising awareness of post-stroke care throughout Texas and California. “The Central Texas Board of Directors continues to guide the American Heart Association as we address health disparities throughout our area,” said Sara Harwood, Region Senior Vice President of the American Heart Association. “The addition of Centre for Neuro Skills and Matt Ashley to our Board brings more insight and ideas as we deepen our understanding and ready for action on all aspects of health and well-being.” During Dr. Ashley’s nine-year tenure at CNS, he has served as a consulting neurologist, treating a diverse spectrum of patients recovering from traumatic and acquired brain injury. Dr. Ashley is a noted speaker, who lectures at universities and seminars focusing on stroke, epilepsy, dementia, neuroradiology and brain injury rehabilitation. Dr. Ashley received both his medical and juris doctor degrees from Southern Illinois University. He completed a neurology residency at UCLA, as well as a neurological rehabilitation fellowship at the university’s renowned Neurological Rehabilitation and Research Unit. CNS opened its newest clinic in Austin in June, 2021. The 17,000 square ft. facility can serve 60 patients and is located at 14425 Falconhead Blvd. ### About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information, visit neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. For a video overview of CNS, visit our YouTube channel. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Visit heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1. Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com American Heart Association Megan Jameson +1 512-338-2639 megan.jameson@heart.org Company Website https://www.neuroskills.com/

May 03, 2023 08:32 AM Pacific Daylight Time

Image
Article thumbnail News Release

Emergent Health Announces Its Return to the “Pink Current Information” Tier on OTC Markets

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space, is pleased to announce that it has regained its “Pink Current Information” status with the OTC Markets, a major milestone in the company's continued growth and development and is now current with all required mandatory disclosure filings again. Jim Morrison, former L'Oréal President and Emergent’s full-time CEO stated “We’ve been working diligently with OTC Markets since being classified as “Pink Sheet Limited Information” several weeks ago and took all the necessary steps to regain “Pink Current Information” status. Achieving this status is a testament to Emergent’s commitment to excellence and full transparency with the intent to create long-term trust and value for our shareholders. Moving forward, we have taken steps to ensure this never occurs again with regard to OTC Market mandatory disclosure requirements. This achievement would not have been possible without the hard work and dedication of our entire team, and we are grateful for their efforts”. Yesterday on May 2, 2023, Emergent announced revenues of $373,406 for the quarter ended December 31, 2022 as compared to $185,471 for the quarter ended September 30, 2022, an increase of over 100% and revenues of $574,613 for the Year Ended December 31, 2022 as compared to $119,567 for the year ended December 31, 2021, an increase of over 380%. The financial statement can be viewed in its entirety at OTC Markets. The global b iologics market size was valued at US $366.43 billion in 2021 and it is expected to hit over US$ 719.84 billion by 2030 with a noteworthy CAGR of 7.8% from 2022 to 2030. A biologic medication is a product that is made from live organisms and contains living organism components. Examples of biologics are Recombinant protein, tissues, allergens, genes, cells, blood components, blood, and vaccinations are all examples of biologics. Examples of what can be treated are Anemia, hemophilia, chronic migraine, hepatitis B, rheumatoid arthritis, inflammatory bowel disease, and other disorders and infections are treated with biologics. Our focus is on aesthetics cosmetics and men’s and women’s health, but also wound care and tissue regeneration. Various government efforts, higher share of biologics in the market, and rising use of biopharmaceuticals over chemically produced molecules, and many other factors are driving the biologics market expansion in the forecast period. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website i nfo@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 03, 2023 10:53 AM Eastern Daylight Time

Article thumbnail News Release

AI Tool Predicts Colon Cancer Survivorship and Response to Treatment

MarketJar

Harvard Medical School and National Cheng Kung University in Taiwan have designed an artificial intelligence (AI) algorithm to improve colorectal cancer prognosis and treatment options. The new technique uses microscopic images of tumor samples to reliably predict colorectal tumor aggressiveness. It predicts survival with and without disease recurrence and the optimum treatment. The new approach may help clinicians recommend more intense follow-ups, aggressive treatments, or clinical trials of newer drugs for individuals with poor prognosis. In areas with limited access to advanced pathology and tumor genetic sequencing, the strategy may be useful. This new AI tool goes beyond mimicking or optimizing human expertise and can see visual patterns on microscope images that the naked eye cannot. The algorithm was trained with patients' ages, sexes, cancer stages, and results using records from almost 2,000 colorectal cancer patients. The tumor's genomic, epigenetic, protein, and metabolic profiles were inputted. The model pathologist was then presented tumor samples and instructed to look for visual markers of tumor types, genetic mutations, epigenetic alterations, disease progression, and patient survival. The researchers showed the model novel pictures of tumor samples from multiple patients to test its "real-world" performance. To evaluate its efficacy, they matched its results to real patients and other clinical data. After diagnosis, survival time and cancer-free years were accurately predicted. The technology also projected how a patient's tumor would respond to certain medications based on genetic variations that made the cancer more or less likely to form or spread. The technique outperformed pathologists and cutting-edge AI algorithms. The researchers believe this approach could assist guide treatment decisions in cases when resources are short or genetic sequencing of tumor tissue is not possible. It could help clinicians and patients navigate colorectal cancer, which kills 1 million people globally each year. When it comes to combating colon cancer, early detection is key. It’s also important that cancer detection is simple, accessible, and affordable. Up until recently, a colonoscopy was the most accurate way to detect colon cancer. However, over one-third of eligible individuals refuse to undergo a colonoscopy, which is why non-invasive alternatives are needed. Mainz Biomed ( NASDAQ:MYNZ ) is the company behind ColoAlert, a highly accurate and easy-to-use at-home screening test for colorectal cancer (CRC). This product is the first DNA-based screening test for colorectal cancer and is already approved in the European Union. Revolutionary At-Home Cancer Screening Test Moves Toward FDA Approval Mainz Biomed 's flagship product ColoAlert, which is based on PCR technology, detects more cases of colorectal cancer than other stool tests and enables for early diagnosis. The product is already commercially available in some EU nations through a network of top independent laboratories, corporate health programs, and direct sales and the company is working towards US approval. The company has already successfully completed its pre-submission process, and IRB approval for its pivotal FDA study, ReconAAsense. That means that FDA approval could potentially be in the future and if that happens, it could send this company into a new dimension. ColoAlert will be tested in a pivotal FDA-registration trial 'ReconAAsense' to acquire commercial approval in the United States. Once licensed in the US, Mainz Biomed ’s goal is to build scalable distribution across the country through a collaborative partner program with regional and national laboratory service providers. Mainz Biomed has joined Eurofins GeLaMed to its network of lab partners delivering PCR test kit processing of ColoAlert. Eurofins GeLaMed is part of Eurofins Scientific, a multinational laboratory business with over 61,000 people in 61 countries and 450 million tests per year. It has four facilities in Germany. Eurofins GeLaMed offers advanced diagnostics in human genetics, medical microbiology, laboratory medicine, and molecular diagnostics in eleven medical departments. GeLaMed's over 500 staff process more than 15,000 orders each day and offer more than 2,000 analytical methods from their laboratory medicine and microbiological portfolios under medical professionals. Eurofins Business Line Director Clinical Diagnostics DACH Marcus Cholewa said he was excited about Mainz Biomed and Eurofins GeLaMed's collaboration because Eurofins always provides excellent customer service, quality, advanced analytical solutions, and the most comprehensive testing methods. He also said that Eurofins has a history of providing innovative and high-value diagnostic testing solutions, and that by working, they might help identify colorectal cancer (CRC) and give patients individualized information to manage their health. Under the agreement, Eurofins GeLaMed will offer ColoAlert at its testing sites and Mainz Biomed will help with physician and patient education programs for March Colorectal Cancer Awareness Month, emphasizing the importance of early screening for CRC detection and prevention. Please visit this link for additional information on Mainz Biomed ( NASDAQ:MYNZ ) and its projects. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) seventy three thousand three hundred forty USD for 17 days (13 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

May 03, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

High School Football National Showcase Returns to Broward County in August 2023

Campus Multimedia

Broward Education Foundation (BEF), a 501(c)3 that supports educational enhancements for the 6 th largest school district in the country, today announced the return of the second annual High School Football National Showcase to Broward County, FL, from Aug. 24-26, 2023. The national showcase will feature 7 of the top 10 ranked High School football teams in the country and will include numerous 4- and 5-star college prospects. ESPN will be broadcasting two of the matchups featuring St. John Bosco (CA) vs St. Thomas Aquinas (NJ) and St. Frances Academy (MD) vs Chaminade-Madonna (FL) which will played at the Brian Piccolo Memorial Stadium on the campus of St. Thomas Aquinas. For a full schedule and game matchups, go to browardedfoundation.org. “Broward County is one of the most talent-rich high school football areas in the country and we look forward to welcoming other elite teams to south Florida,” said James A. Knapp, Director of Advancement, Broward Education Foundation. “The National High School Football Showcase in Broward County is a premier event that celebrates amazing teams, players, and coaches. The return of the Broward County Football Showcase will host a hotbed of future star talent over a weekend that will capture that nation’s attention as top-ranked high school athletes face off in person and streamed across ESPN and FloSports. Campus Multimedia will act as the exclusive strategic sponsorship partner for the High School National Football Showcase and will be responsible for commercial partnerships. Campus Multimedia has a passion to support the nation’s 77,000+ schools by bringing brand generosity to students, schools, and school districts. This mission aligns with Broward County’s values and hopes to see its community prosper. About Broward County Education Foundation Broward Education Foundation is the only 501(c)3 charitable organization solely dedicated to supporting Broward County Public Schools and serves as a catalyst for educational excellence by providing teacher grants to fund development of innovative curriculum that advances Pre K-12 achievement; vitally needed school supplies for Title I school students, and scholarships for qualified high school seniors. Established in 1983, the non-profit Broward Education Foundation contributes more than $3 million to Broward County Public Schools annually. About Campus Multimedia Campus Multimedia (CM) is on a mission to improve school life for students, teachers, and school districts through brand partnership programs that meet school needs. Its extensive network of 77,000+ school relationships creates an unparalleled impact for brands to step inside schools at scale with mutually beneficial goals. As the leader in school marketing execution, CM creates platforms for brands to achieve their goals and schools to receive resources. Learn more at campusmultimedia.com ### Contact Details Eric Nemeth nemeth@ericpr.com Company Website https://www.campusmultimedia.com/

May 03, 2023 08:57 AM Eastern Daylight Time

Article thumbnail News Release

NAVEX Opens Nominations for 2023 Customer Excellence Awards

NAVEX Global

NAVEX, the leader in integrated risk and compliance management software, today announced nominations are now open for the third annual NAVEX Customer Excellence Awards. This prestigious award acknowledges and celebrates the exceptional performance of NAVEX customers’ ethics, compliance and integrated risk management programs. The nomination window will be open until July 12, 2023. Previous Customer Excellence Award winners include Dell Technologies, Castolin Eutectic Holding GmbH, Jacksonville Transportation Authority and Genpact. Interested NAVEX customers can submit their entry today via the NAVEX Customer Excellence Award website. “A robust risk and compliance program is fundamental to creating and maintaining a highly motivated workplace culture,” said Steve Chapman, Chief Customer Officer at NAVEX. “Our annual excellence awards recognize especially strong programs that demonstrate measurable impact on business success. We look forward to seeing all of this year’s nominations.” The Customer Excellence Awards recognize exceptional program performances from NAVEX's 13,000+ customers worldwide, covering 70 million employees, categorized by company size and across three categories. Ethics & Compliance – Recognizes the exceptional ability to identify and mitigate risks, provide meaningful insights into corporate culture and drive risk aware decision-making through E&C programs. Integrated Risk Management – Recognizes the exceptional ability to adapt to specific risk landscapes, bring visibility to risk across the organization and use informed data to influence decisions that ultimately make for a more resilient and successful business. GRC Program of the Year – Recognizes the exceptional ability to break down silos across the business to align ethics and compliance, and/or integrated risk management, resulting in a comprehensive risk and compliance management program that provides efficiency and actionable insights. As in years past, an expert panel of judges will determine the winners, consisting of some of the most respected names in the industry, including Vera Cherepanova, Studio Etica; Matt Kelly, Radical Compliance; Michael Volkov, The Volkov Law Group; Kyle Welch, George Washington School of Business; Carol Williams, Strategic Decision Solutions; along with NAVEX executives Florian Haarhaus, International General Manager; Steve Chapman, Chief Customer Officer; and Carrie Penman, Chief Risk & Compliance Officer. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Scott Levesque +1 617-388-5773 scott.levesque@navex.com Company Website https://www.navex.com

May 03, 2023 08:30 AM Eastern Daylight Time

1 ... 7475767778 ... 273